Celon Pharma S.A. (WSE:CLN)

Market Cap	1.14B -11.5%
Revenue (ttm)	226.35M +7.6%
Net Income	-122.11M
EPS	-2.35
Shares Out	53.86M
PE Ratio	n/a
Forward PE	344.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,323
Open	21.20
Previous Close	21.10
Day's Range	20.95 - 21.40
52-Week Range	18.50 - 25.30
Beta	0.72
Analysts	Hold
Price Target	20.44 (-3.13%)
Earnings Date	Sep 16, 2026

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 566
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2024, Celon Pharma's revenue was 205.55 million, a decrease of -4.25% compared to the previous year's 214.66 million. Losses were -34.45 million, 22.5% more than in 2023.